Sponsored by:
The Development–GMP Gap
Why do so many drug development programs lose momentum as they transition from product development into clinical manufacturing?
Why CDMO Performance Drops Exactly When It Matters Most
Why do so many drug development programs lose momentum as they transition from product development into clinical manufacturing?
This white paper explores the often-overlooked disconnect between formulation development and GMP execution that can lead to delays, inefficiencies, and frustration for pharmaceutical and biotechnology organizations. Drawing on industry observations and sponsor experiences, it reveals how these challenges are frequently rooted not in science, but in organizational structure, communication, and operational handoffs.
By comparing traditional task-based operating models with integrated, program-based approaches, the paper demonstrates how cross-functional alignment, early GMP planning, continuous knowledge management, and technical continuity can significantly improve clinical readiness and manufacturing success.
What You'll Learn
- Why scientifically successful programs often lose momentum during GMP manufacturing
- How organizational silos and poor knowledge transfer create delays and inefficiencies
- How integrated, cross-functional approaches improve clinical readiness and manufacturing success
Download this white paper to discover how integrated development and GMP strategies can help maintain momentum, improve execution, and drive successful clinical manufacturing outcomes.
